Scholar Rock Holding Corporation (SRRK)

Market Cap	4.59B
Revenue (ttm)	n/a
Net Income	-353.43M
EPS	-3.56
Shares Out	102.01M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	686,213
Open	44.00
Previous Close	43.13
Day's Range	43.83 - 45.96
52-Week Range	22.71 - 48.28
Beta	0.64
Analysts	Strong Buy
Price Target	51.20 (+13.9%)
Earnings Date	Feb 26, 2026

About SRRK

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFβ) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for development of monoclonal antibodies that locally and selectively target the precursor. The company develops Apitegromab...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 24, 2018
• Employees: 128
• Stock Exchange: NASDAQ
• Ticker Symbol: SRRK
• Website: https://www.scholarrock.com

Analyst Summary

According to 11 analysts, the average rating for SRRK stock is "Strong Buy." The 12-month stock price target is $51.2, which is an increase of 13.90% from the latest price.

Price Target

$51.2

(13.90% upside)

Analyst Consensus: Strong Buy